Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24483790 | 0.87 | CYP11B2 (0.45) | CYP11B2KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12253238 | 0.85 | CYP11B2 (0.32) | CYP11B2MEN1KMT2A | |
| SCHEMBL22952638 | 0.83 | CYP11B2 (0.39) | CYP11B2KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14706713 | 0.78 | TRPA1 (0.32) | MEN1KMT2ATRPA1 | |
| SCHEMBL16705383 | 0.77 | CYP11B2 (0.44) | CYP11B2KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10183419 | 0.76 | MAPK1 (0.37) | CYP11B2KDM4ESMN1; SMN2ALDH1A1GAA | |
| SCHEMBL21719514 | 0.74 | — | — | |
| SCHEMBL12121231 | 0.74 | CYP11B2 (0.45) | CYP11B2KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21241219 | 0.74 | LRRK2 (0.45) | CYP11B2KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10183724 | 0.74 | LRRK2 (0.36) | CYP1A2ALDH1A1LRRK2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-8507490-B2 | Tetrasubstituted pyridazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507490-B2 | Tetrasubstituted pyridazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8455398-B2 | Amide compounds, preparation methods and uses thereof | SINOCHEM CORPORATION (CN) | 2013-06-04 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110263602-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263602-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110046152-A1 | Amide Compounds, Preparation Methods and Uses Thereof | SINOCHEM CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | CYP11B2 1428/4885KDM4E 3386/4885CYP1A2 980/4885 |
| US-20110046152-A1 | Amide Compounds, Preparation Methods and Uses Thereof | ACHE, MGAM, PGLS | CYP11B2 3569/4885KDM4E 371/4885CYP1A2 1378/4885 |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP11B2 1579/4885KDM4E 2437/4885CYP1A2 540/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP11B2 1907/4885KDM4E 2800/4885CYP1A2 767/4885 |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP11B2 462/4885KDM4E 3365/4885CYP1A2 424/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP11B2 1579/4885KDM4E 2437/4885CYP1A2 540/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | CYP11B2 591/4885KDM4E 2294/4885CYP1A2 456/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP11B2 649/4885KDM4E 3568/4885CYP1A2 634/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP11B2 1907/4885KDM4E 2800/4885CYP1A2 767/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP11B2 643/4885KDM4E 3494/4885CYP1A2 618/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | CYP11B2 681/4885KDM4E 2066/4885CYP1A2 996/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP11B2 1579/4885KDM4E 2437/4885CYP1A2 540/4885 |
| US-20110263602-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, SMO, GLI1 | CYP11B2 4588/4885KDM4E 702/4885CYP1A2 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.